Advanced search    

Search: authors:"Prajnan Das"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma

Background A strong dose-volume relationship exists between the amount of small bowel receiving low- to intermediate-doses of radiation and the rates of acute, severe gastrointestinal toxicity, principally diarrhea. There is considerable interest in the application of highly conformal treatment approaches, such as intensity-modulated radiation therapy (IMRT), to reduce dose to ...

Reirradiation to the abdomen for gastrointestinal malignancies

Background Reirradiation to the abdomen could potentially play a role in palliation of symptoms or local control in patients with gastrointestinal malignancies. Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen. Methods Between November 2002 ...

ACR Appropriateness Criteria® Resectable Rectal Cancer

Radiation Oncology ACR Appropriateness Criteria William E Jones III 8 Charles R Thomas Jr 0 Joseph M Herman 7 May Abdel-Wahab 13 Nilofer Azad 12 William Blackstock 11 Prajnan Das 10 Karyn A Goodman ... reported “Nucletron, Genentech” As of June 27, 2011, Prajnan Das, MD reported “Research Support – Genentech” For the remaining authors none were declared. Authors’ contribution WJ, CT, JM, MW, NA, WB, PD

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other ...